Catalent strengthens leadership position in Asia-Pacific
Company announces key appointments and a new sales office in Korea.
Catalent Pharma Solutions has announced two key appointments and the opening of a new sales office in Korea to support the company’s continued investment and strategic growth plans in the Asia Pacific region.
Howard Kim has joined the company in the role of Director of Business Development in Korea, and will work between Catalent’s new sales office in Seoul, South Korea, and the company’s Somerset, NJ, headquarters. Mr Kim will manage business development activities across all of Catalent’s business units in the expanding Korean market.
Prior to joining Catalent, Mr Kim was responsible for developing businesses for Korean pharmaceutical companies in the US and in Europe. He has also worked for Novartis, Sandoz, Schering-Plough, Wyeth, and Merck in the areas of product supply and planning.
In a second appointment, Erin Vlack has been promoted to Manager of the company’s new Clinical Supply Services site in Kakegawa, Japan, which is to provide secondary packaging, labeling, storage and distribution capabilities locally.
In this role, Ms Vlack will establish and lead the site’s clinical supply operations, driving the business strategy, achieving necessary regulatory standards, meeting on-time delivery, quality, and efficiency targets, and establishing safe working practices within the site’s cGMP environment.
Ms Vlack has 12 years of progressive project management experience, a decade of which spans Japanese business strategy, contract manufacturing, pharmaceutical and clinical trial logistics, and supply and depot management. Since joining Catalent in April 2015, Ms Vlack has held the role of Project Manager at the company’s Morrisville, North Carolina facility in the US. Prior to this she lived, studied and worked in and around Japan for over 20 years.
Catalent has offered clinical supply services in the region since 2005, and within the past 3 years has made significant capital investments totaling more than $10 million with additional personnel to expand its overall Asia-Pacific footprint to meet growing customer demand. Today, the company’s network spans nine audited depots and three fully owned and operated clinical packaging facilities in China, Singapore, and Japan when it opens for business later this year. Available services include primary and secondary packaging, demand led supply services, clinical storage, cold chain services, global distribution, comparator sourcing, project management, clinical supply management, regulatory consulting, and returns and destruction.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance